Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

280.56 -1.56 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Expert Ratings For Insulet
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter: 
Via Benzinga
52 Biggest Movers From Friday
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Provention Bio (NASDAQ:PRVB) stoc... 
Via Benzinga
FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above
The 
Via Benzinga
Mid-Day Market Update: US Stocks Turn Positive; Nasdaq Surges 2%
US stocks turned higher, with all the three major indices recording gains. The Nasdaq climbed more than 2% following stronger-than-expected earnings results from Apple Inc. (... 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF... 
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX
Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares... 
Via Benzinga
Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control
From Insulet Corporation
Via Business Wire
If You Invested $100 In This Stock 5 Years Ago, Here's How Much You Would Have Today
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.86% on an annualized basis. Buying $100 In PODD: 5 years ago, an investor could have purchased 2.30... 
Via Benzinga
This Foreboding Sign Looms Over Insulet's Chart
If history is any guide, there may be trouble ahead for shares of Insulet (NASDAQ:PODD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
From Insulet Corporation
Via Business Wire
Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
From Insulet Corporation
Via Business Wire
Insulet to Present at Nasdaq’s 45th Investor Conference
From Insulet Corporation
Via Business Wire
10 Biggest Price Target Changes For Monday
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wedbush raised Uber Technologies, Inc. (NYSE:UBER)... 
Via Benzinga
Insulet Corporation (PODD) Q3 2021 Earnings Call Transcript
PODD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Insulet Posts Mixed Third Quarter, But Raises Sales Guide On Narrow Beat
Insulet raised its full-year sales outlook Thursday on its third-quarter sales beat. 
Via Investor's Business Daily
Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet Honors Diabetes Awareness with Global Activities and Events
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford
From Insulet Corporation
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System. Omnipod 5 is a... 
Via Benzinga
Insulet’s Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
From Insulet Corporation
Via Business Wire
Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021
From Insulet Corporation
Via Business Wire
5 Top Stocks for September
Our analysts give you five picks you can add to your portfolio today. 
Via The Motley Fool
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Looking into Insulet's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Insulet (NASDAQ:PODD) earned $26.30 million, a 61.35% increase from the preceding quarter. Insulet also posted a... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.